Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.

European journal of haematology·2026

Same author

Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.

British journal of haematology·2025

Same author

Comparison of 162 mg and 81 mg Aspirin for Prevention of Preeclampsia: A Randomized Controlled Trial.

Obstetrics and gynecology·2025

Same author

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Leukemia·2025

Same author

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.

Blood·2025

Same author

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Scientific reports·2025

Search research articles

Related Experiment Video

Updated: May 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Emil Kuriakose¹, Katherine Vandris, Y Lynn Wang

¹Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, NY 10021, USA.

|November 22, 2011

Summary

This summary is machine-generated.

A reduction in the JAK2(V617F) allele burden is not required for patients with polycythemia vera to achieve hematologic remission. Molecular response is not consistently accompanied by clinical response in polycythemia vera.

Related Experiment Videos

Last Updated: May 27, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Area of Science:

Hematology
Molecular Biology
Oncology

Background:

The JAK2(V617F) allele burden is a potential marker for monitoring polycythemia vera treatment response.
Its role as a prerequisite for hematologic remission remains unclear.

Purpose of the Study:

To determine if a reduction in the JAK2(V617F) allele burden is necessary for achieving hematologic remission in polycythemia vera patients undergoing cytoreductive therapy.

Main Methods:

A cohort of 73 polycythemia vera patients treated with interferon or non-interferon therapies were analyzed.
Hematologic response was assessed using Polycythemia Vera Study Group criteria.
Molecular response was evaluated using European Leukemia Net criteria for JAK2(V617F) allele burden reduction.

Main Results:

High rates of hematologic response were observed with both interferon (89.1%) and non-interferon (59.3%) treatments.
Molecular response rates were low across all treatment groups (15.2% for interferon, 7.4% for non-interferon).
There was poor statistical agreement between hematologic and molecular responses.

Conclusions:

Hematologic response in polycythemia vera is often not associated with a reduction in the JAK2(V617F) allele burden.
Quantitative changes in the JAK2(V617F) allele burden are not a mandatory requirement for clinical response in polycythemia vera.